Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 10, 2026 09:15 ET | Source: MAIA Biotechnology, Inc.

MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial

Additional data from MAIA’s THIO-101 expansion may further support an accelerated approval filing with the FDA Potential breakthrough therapy holds substantial commercial opportunity in a projected...
June 04, 2026 09:45 ET | Source: MAIA Biotechnology, Inc.

MAIA Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial

MAIA’s novel telomere-targeting therapy being evaluated as a third-line treatment for advanced non-small cell lung cancer CHICAGO, June 04, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE...
May 19, 2026 05:00 ET | Source: Genosafe

GenoSafe advances CLIA pathway for transatlantic ATMP development

GenoSafe advances CLIA pathway for transatlantic ATMP development CLIA registration enables GenoSafe to support testing of samples from U.S.-based patients enrolled in clinical trials.This milestone...
May 18, 2026 17:15 ET | Source: DRC

DRC Congratulates Sarah Eddy, William Savitt, and the Wachtell and Morrison Foerster Trial Team on Their Victory for OpenAI in Musk, et al. v. Altman, et al.

DRC congratulates its clients on their victory on behalf of OpenAI in Musk, et al. v. Altman, et al.
May 12, 2026 09:00 ET | Source: Resolution Therapeutics

Resolution Therapeutics to showcase key preclinical data on its Regenerative Macrophage Therapy (RMT) RTX001 in oral presentation at ASGCT 2026

Resolution Therapeutics will present key preclinical data today on its RMT RTX001 in an oral presentation at the ASGCT Annual Meeting
April 23, 2026 07:30 ET | Source: Marvel Biosciences Corp.

Marvel Biosciences to Participate and Present at the 2nd Neuroscience Innovation Partnering and Licensing Summit

Marvel Biosciences to participate in 2nd Neuroscience Innovation Partnering & Licensing Summit, allowing Marvel to showcase its progress on global stage
April 01, 2026 08:02 ET | Source: Quantum BioPharma

Quantum BioPharma Submits Investigational New Drug (IND) Application to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple Sclerosis

TORONTO, April 01, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a...
February 03, 2026 11:00 ET | Source: Rafferty Domnick Cunningham & Yaffa

Rafferty Domnick Cunningham & Yaffa to Try Palm Beach County Medical Malpractice Case Against South Florida Anesthesia and Affiliated Providers

Rafferty Domnick Cunningham & Yaffa announce they will try a medical malpractice case. Sean C. Domnick and Nicole Kruegel will be trying the case.
January 06, 2026 11:50 ET | Source: Dubin Research and Consulting

Distinguished Trial Attorney Joseph Conza Brings 30 Years of Courtroom Expertise to DRC as a Director of Litigation Strategy

Dubin Research & Consulting (“DRC”) hires experienced trial attorney Joseph (“Joe”) Conza, Esq., as a Director of Litigation Strategy.
December 17, 2025 08:45 ET | Source: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Doses First Patient in Phase 2 Alzheimer’s Clinical Trial

First Patient Dosed with Intranasal Foralumab in Randomized, Placebo-Controlled Phase 2 TrialBuilds on Recent Evidence of Persistent Neuroinflammation in Alzheimer’s Patients Treated with Anti-Amyloid...